Delivery Order SPE2DB24D2003-SPE2DB25FXLL9
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 ml pen injections, with a ceiling value of $1,143.87 and an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child delivery...
- The Defense Logistics Agency awarded a delivery order contract valued at $3,813.85 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. This competitive, firm fixed-price delivery order is set to be completed by July 28, 2025, with performance occurring at the company's corporate headquarters in Conshohocken, Pennsylvania. The award represents a child order issued under a larger contract vehicle supporting the federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a ceiling value of $7,724.28. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-competitive, non-set-aside award. The product will be delivered to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This award is issued as a child...
- The Defense Logistics Agency awarded a delivery order valued at $5,431.13 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pens on July 23, 2025, with an ultimate completion date of July 24, 2025. The contract represents a firm fixed price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,525.20 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on July 25, 2025, with completion scheduled for July 28, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $2,697.75 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injections. The contract is a firm fixed-price delivery order with no set-aside designation, reflecting AmerisourceBergen's ability to compete successfully in open federal procurement. Performance will be completed by July 21, 2025, with fulfillment occurring at the contractor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pen injections, with a ceiling value of $2,287.74. The award, issued on July 24, 2025, represents a firm fixed price delivery order with a completion date of July 25, 2025, indicating a short-duration, expedited fulfillment requirement. This contract was competitively awarded without set-aside designations, executed under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a $37,571.53 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 ml pen injections. This delivery order, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a small-value pharmaceutical procurement under a larger indefinite delivery contract framework. The contract was competitively awarded with no set-aside designation, and performance will be executed from...
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens with a ceiling value of $3,072.24. The contract, which was competitively awarded with no set-aside designation, has a firm fixed price structure and an ultimate completion date of August 8, 2025. AmerisourceBergen will perform this work from its corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $21,483.49 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injectors on July 28, 2025, with an ultimate completion date of July 29, 2025. The contract was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXLL9Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections valued at $10,445.54 on August 7, 2025, with completion scheduled for August 8, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.999 billion prime vendor agreement running through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls within AmerisourceBergen's comprehensive pharmaceutical supply mission supporting the Defense Health Agency and other federal healthcare systems. As a major pharmaceutical distributor, AmerisourceBergen maintains an extensive portfolio of brand-name and generic medications across multiple therapeutic domains through its DLA contracts. The Zepbound acquisition supports military healthcare operations requiring diabetes and weight management pharmaceutical commodities, consistent with the company's established role as a critical vendor for federal medical procurement across the military healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.4k | 8/7/25 |